中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

6 records (took 0.017 seconds)

    3-(6-ALKOXY-5-CHLOROBENZO[D]ISOXAZOL-3-YL)PROPANOIC ACID USEFUL AS KYNURENINE MONOOXYGENASE INHIBITORS
    1.
    发明申请
    3-(6-ALKOXY-5-CHLOROBENZO[D]ISOXAZOL-3-YL)PROPANOIC ACID USEFUL AS KYNURENINE MONOOXYGENASE INHIBITORS 有权

    公开(公告)号：US20170349577A1

    公开(公告)日：2017-12-07

    申请号：US15537805

    申请日：2015-12-17

    Applicant: GlaxoSmithKline Intellectual Property Development Limited

    Inventor： Anne Marie Jeanne BOUILLOT ,  Alexis DENIS ,  Ann Louise WALKER ,  John LIDDLE

    IPC: C07D413/12

    CPC classification number: C07D413/12

    Abstract: Compound of formula (I) wherein: R1 is heteroaryl either unsubstituted or substituted by methyl, ethyl, halo or ═O; and R2 is H, methyl or ethyl; and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

    3-(5-CHLORO-2-OXOBENZO[D]OXAZOL-3(2H)-YL) PROPANOIC ACID DERIVATIVES AS KMO INHIBITORS
    3.
    发明申请
    3-(5-CHLORO-2-OXOBENZO[D]OXAZOL-3(2H)-YL) PROPANOIC ACID DERIVATIVES AS KMO INHIBITORS 审中-公开
    作为KMO抑制剂的3-（5-氯代-2-氧代苯并[D]氧杂唑-3（2H） - 基）丙酸衍生物

    公开(公告)号：US20160318884A1

    公开(公告)日：2016-11-03

    申请号：US15104821

    申请日：2014-12-17

    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

    Inventor： Anne Marie Jeanne BOUILLOT ,  Olivier MIRGUET ,  John LIDDLE ,  Anne Louise WALKER

    IPC: C07D263/58 ,  C07C215/10 ,  C07C211/27 ,  C07C211/13 ,  C07C279/14 ,  C07C229/26 ,  C07C309/30 ,  C07D413/12 ,  C07C223/02

    Abstract: A compound of formula (I) or a salt thereof are provided: wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

    Abstract translation: 其中R1，X和R3在本说明书中定义，可用于治疗KMO介导的疾病，例如急性胰腺炎，慢性肾脏疾病，与全身炎症反应综合征（SIRS），亨廷顿舞蹈病，阿尔茨海默病，脊髓小脑性共济失调相关的其他病症 ，帕金森病，艾滋病 - 痴呆综合征，肌萎缩性侧索硬化（ALS），抑郁症，精神分裂症，败血症，心血管休克，严重创伤，急性肺损伤，急性呼吸窘迫综合征，急性胆囊炎，严重烧伤，肺炎，广泛的外科手术，缺血 肠，严重急性肝病，严重急性肝性脑病或急性肾功能衰竭。

    COMPOUNDS
    5.
    发明申请
    COMPOUNDS 审中-公开

    公开(公告)号：US20180127405A1

    公开(公告)日：2018-05-10

    申请号：US15574506

    申请日：2016-05-19

    Applicant: GlaxoSmithKline Intellectual Property Development Limited

    Inventor： Anne Marie Jeanne BOUILLOT ,  Alexis DENIS ,  John LIDDLE ,  Ann Louise WALKER

    IPC: C07D417/12

    CPC classification number: C07D417/12

    Abstract: Compounds of formula (I) wherein: R1 is heteroaryl optionally substituted by methyl, ethyl, halo or =0; and R2 is H, methyl or ethyl. and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel disease, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

Patent Agency Ranking